Skip to content
OpenCapital
Get started

MoonLake Immunotherapeutics MLTX Unrealized Gains on Investments

Unrealized Gains on Investments at other companies

Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$73K+82.5%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
——
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
——

Other financials

Income statement

See full
Operating income-$70.0M-47.5%
Net income-$69.7M-74.5%
EPS (diluted)-$0.98-55.6%

Balance sheet

See full
Cash & equivalents$298.5M+9.9%
Total debt$100.8M+33.3%
Total equity$254.0M-37.7%
Total assets$400.4M-21.7%

Cash flow

See full
Operating cash flow-$66.3M-73.8%
CapEx--100%
Free cash flow-$66.3M-73.6%

Valuation

See full
Market cap$1.49B-45.9%
Enterprise value$1.29B-50.0%

Returns & leverage

See full
Return on equity-77.7%-221pp
Debt / equity0.4×+0.2×
Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's unrealized gains on investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MoonLake Immunotherapeutics's unrealized gains on investments?
MoonLake Immunotherapeutics (MLTX) reported unrealized gains on investments of $362K in Q1 2026.
How has MoonLake Immunotherapeutics's unrealized gains on investments changed year-over-year?
MoonLake Immunotherapeutics's unrealized gains on investments decreased by 86.3% year-over-year, from $2.65M to $362K.